Related Experiment Videos
BTA-TRAK--a useful diagnostic tool in urinary bladder cancer?
B Mahnert1, S Tauber, M Kriegmair
1Institute of Clinical Chemistry, Ludwing-Maximilians-University, Munich, Germany.
Anticancer Research
|September 2, 1999
Summary
The BTA-TRAK assay shows limited clinical utility for bladder cancer diagnosis. This study found insufficient sensitivity and specificity, indicating it cannot replace cystoscopy or improve current diagnostic strategies.
Area of Science:
- Urology
- Oncology
- Diagnostic Assays
Background:
- The BTA-TRAK assay has been investigated for its clinical utility in bladder cancer management.
- Previous studies suggested potential value in diagnosing bladder tumors.
Purpose of the Study:
- To prospectively evaluate the diagnostic performance of the BTA-TRAK assay in patients undergoing cystoscopy.
- To determine the sensitivity and specificity of the BTA-TRAK assay for detecting active bladder tumors.
Main Methods:
- A prospective study involving 244 consecutive patients undergoing cystoscopy.
- Voided urine samples were analyzed using the BTA-TRAK assay with various cutoff values.
- Performance was assessed against benign urological diseases, healthy individuals, and patients with and without recurrence.
Main Results:
- With a cutoff of 1300 U/mL, specificity for benign conditions was 95%, but sensitivity for active tumors was only 13%.
- Using the manufacturer's recommended cutoff (14 U/mL), sensitivity was 62% and specificity was 54%.
- The assay demonstrated insufficient diagnostic accuracy across tested parameters.
Conclusions:
- The BTA-TRAK assay exhibits inadequate specificity and sensitivity for bladder cancer detection.
- It is not a suitable replacement for cystoscopy in diagnostic strategies.
- The assay does not improve current diagnostic approaches for bladder cancer.